The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

fluocinolone     (6S,8S,9S,10S,11S,13S,14S,16R, 17R)-6,9...

Synonyms: CHEMBL1201390, SureCN2921319, KST-1A8568, AR-1A7027, LS-118445, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of fluocinolone


High impact information on fluocinolone


Chemical compound and disease context of fluocinolone


Biological context of fluocinolone


Anatomical context of fluocinolone


Associations of fluocinolone with other chemical compounds


Gene context of fluocinolone

  • The specific activity of epidermal transglutaminase (total epidermal transglutaminase/total soluble epidermal protein) was decreased by retinoic acid treatment; was maintained at normal levels by anthralin (except for the 7-day point where it decreased 50%); and was dramatically stimulated by fluocinolone acetonide [24].
  • The latter two phenomena can be prevented by fluocinolone acetonide (10(-8) M), i.e. by inhibition of phospholipase A2 (PLA2) [25].
  • The first group (n = 28) was treated with a 0.1% solution of fluocinolone acetonide (FAS), the second group (n = 22) with 0.1% fluocinolone acetonide in orabase (FAO), and the third group (n = 47) with both FAS and FAO (FAS/FAO) throughout the study [26].
  • This article describes a long-term, multicenter, open-label, 12-month study of once-daily fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05% (Tri-Luma Cream, hereinafter called TC [triple combination]) application in the treatment of melasma [27].

Analytical, diagnostic and therapeutic context of fluocinolone


  1. Evidence for a new model of tumor progression from carcinogenesis and tumor promotion studies with 7-bromomethylbenz[a]anthracene. Scribner, J.D., Scribner, N.K., McKnight, B., Mottet, N.K. Cancer Res. (1983) [Pubmed]
  2. Effect of fluocinolone acetonide cream on human skin blood flow. Chimoskey, J.E., Holloway, G.A., Flanagan, W.J. J. Invest. Dermatol. (1975) [Pubmed]
  3. Fluocinolone acetonide sustained drug delivery device to treat severe uveitis. Jaffe, G.J., Ben-Nun, J., Guo, H., Dunn, J.P., Ashton, P. Ophthalmology (2000) [Pubmed]
  4. Ethnic considerations in the treatment of Hispanic and Latin-American patients with hyperpigmentation. Hexsel, D., Arellano, I., Rendon, M. Br. J. Dermatol. (2006) [Pubmed]
  5. Betamethasone dipropionate cream for the treatment of psoriasis. A collaborative evaluation. Charney, P. Archives of dermatology. (1976) [Pubmed]
  6. Ability of the Ca2+ ionophores A23187 and ionomycin to mimic some of the effects of the tumor promoter 12-O-tetradecanoylphorbol-13-acetate on hydroperoxide production, ornithine decarboxylase activity, and DNA synthesis in mouse epidermis in vivo. Perchellet, E.M., Jones, D., Perchellet, J.P. Cancer Res. (1990) [Pubmed]
  7. Development of an in vitro analogue of initiated mouse epidermis to study tumor promoters and antipromoters. Hennings, H., Robinson, V.A., Michael, D.M., Pettit, G.R., Jung, R., Yuspa, S.H. Cancer Res. (1990) [Pubmed]
  8. Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device. Jaffe, G.J., Yang, C.H., Guo, H., Denny, J.P., Lima, C., Ashton, P. Invest. Ophthalmol. Vis. Sci. (2000) [Pubmed]
  9. Relative lack of systemic effects of mometasone furoate on Langerhans cells of mice after topical administration as compared with other glucocorticosteroids. Belsito, D.V., Baer, R.L., Schultz, J.M., Thorbecke, G.J. J. Invest. Dermatol. (1988) [Pubmed]
  10. The effect of fluocinolone acetonide and 12-O-tetradecanoyl-phorbol-13-acetate on the binding and biological activity of epidermal growth factor in rat fibroblasts. Lockyer, J.M., Bowden, G.T., Magun, B.E. Carcinogenesis (1983) [Pubmed]
  11. Cost-effectiveness of a fixed combination of hydroquinone/tretinoin/fluocinolone cream compared with hydroquinone alone in the treatment of melasma. Cestari, T., Adjadj, L., Hux, M., Shimizu, M.R., Rives, V.P. Journal of drugs in dermatology : JDD (2007) [Pubmed]
  12. Mometasone furoate ointment and cream 0.1 percent in treatment of psoriasis: comparison with ointment and cream formulations of fluocinolone acetonide 0.025 percent and triamcinolone acetonide 0.1 percent. Medansky, R.S., Bressinck, R., Cole, G.W., Deeken, J.H., Ellis, C.N., Guin, J.D., Herndon, J.H., Lasser, A.E., Leibsohn, E., Menter, M.A. Cutis; cutaneous medicine for the practitioner. (1988) [Pubmed]
  13. Plasma cortisol studies with 0.05% halometasone cream and ointment in patients with psoriasis. Tomasini, C., Castiglioni, G. J. Int. Med. Res. (1983) [Pubmed]
  14. Effect of prolonged treatment with levamisole on vitiligo with limited and slow-spreading disease. Pasricha, J.S., Khera, V. International journal of dermatology. (1994) [Pubmed]
  15. Characterization of the anti-inflammatory activity and reduced potential for dermal atrophy of (11 beta, 16 beta)-9-fluoro-1',2',3', 4'-tetrahydro-11,21-dihydroxypregna-1,4-dieno[16,17-b]naph thalene-3, 20-dione hydrate (1 : 1) (SQ 26,490), a topically active corticoid. Wojnar, R.J., Alpaugh, W.C., Dzelzkalns, E. Arzneimittel-Forschung. (1985) [Pubmed]
  16. Flunisolide: a review of its pharmacological properties and therapeutic efficacy in rhinitis. Pakes, G.E., Brogden, R.N., Heel, R.D., Speight, T.M., Avery, G.S. Drugs (1980) [Pubmed]
  17. Drug-induced reversion of progression phenotype is accompanied by reversion of AP-1 phenotype in JB6 cells. Lavrovsky, V., Dong, Z., Ma, W.Y., Colburn, N. In Vitro Cell. Dev. Biol. Anim. (1996) [Pubmed]
  18. Effect of toxins on arachidonic acid metabolism in rat cultured pulmonary alveolar macrophages. Naseem, S.M., Hines, H.B., Creasia, D.A. Biochem. Int. (1989) [Pubmed]
  19. In vivo effects of Sn-1,2-dioctanoylglycerol, TPA and A23187 on hamster cheek pouch epithelium. Singh, B.B., McKinney, R.V., Schuster, G.S., Erbland, J.F., Baker, R.L. J. Oral Pathol. (1988) [Pubmed]
  20. A possible correlation between the blood leukocyte formula and the use of glucocorticoids as growth promoters in beef cattle. Brambilla, G., Fiori, M., Pierdominici, E., Antonucci, G., Giorgi, P., Ramazza, V., Zucchi, M. Vet. Res. Commun. (1998) [Pubmed]
  21. Effects of immunosuppressive chemicals on lymphoid development in foetal thymus organ cultures. d'Argy, R., Bergman, J., Dencker, L. Pharmacol. Toxicol. (1989) [Pubmed]
  22. Effects of the phorbolester TPA and of the ionophore A 23187 on phospholipase A2 and C activities in the mouse epidermal cell line HEL-30. Fürstenberger, G., Rogers, M., Faberman, J., Ganss, M., Richter, H., Marks, F. J. Cancer Res. Clin. Oncol. (1987) [Pubmed]
  23. In vitro and ex vivo binding to uterine progestin receptors of the rat as a tool to assay progestational activity of glucocorticoids. Luzzani, F., Gallico, L., Glässer, A. Methods and findings in experimental and clinical pharmacology. (1982) [Pubmed]
  24. The effect of topical drugs on mouse ear epidermal transglutaminase activity. De Young, L., Ballaron, S. J. Invest. Dermatol. (1982) [Pubmed]
  25. Dual effect of the phorbol ester TPA on arachidonic acid release from HeLa cells. Kaszkin, M., Espe, U., Fürstenberger, G., Kinzel, V. FEBS Lett. (1988) [Pubmed]
  26. Clinical evaluation in treatment of oral lichen planus with topical fluocinolone acetonide: a 2-year follow-up. Thongprasom, K., Luengvisut, P., Wongwatanakij, A., Boonjatturus, C. J. Oral Pathol. Med. (2003) [Pubmed]
  27. Hydroquinone 4%, tretinoin 0.05%, fluocinolone acetonide 0.01%: a safe and efficacious 12-month treatment for melasma. Torok, H.M., Jones, T., Rich, P., Smith, S., Tschen, E. Cutis; cutaneous medicine for the practitioner. (2005) [Pubmed]
  28. Determination of fluocinolone acetonide in pharmaceutical preparations by differential-pulse polarography. Leung, C.P., Tam, S.Y. The Analyst. (1981) [Pubmed]
  29. Efficacy of low-release-rate fluocinolone acetonide intravitreal implants to treat experimental uveitis. Mruthyunjaya, P., Khalatbari, D., Yang, P., Stinnett, S., Tano, R., Ashton, P., Guo, H., Nazzaro, M., Jaffe, G.J. Arch. Ophthalmol. (2006) [Pubmed]
WikiGenes - Universities